anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Biology == A tropical species, the lesser mealworm thrives in warm, humid environments, both natural and established by humans. It inhabits caves, rodent nests, and the nests of birds, including kites, pigeons, hamerkop, house sparrow, and purple martin. It easily colonizes agricultural establishments with abundant food sources and warm conditions, such as grain processing and storage facilities and poultry housing. The beetle consumes a wide variety of materials, including litter, bird droppings and bat guano, mold, feathers, eggs, and carrion. It feeds on the eggs and larvae of other insects, such as the rice moth (Corcyra cephalonica). It also engages in cannibalism. It commonly feeds on sick or weakened live animals. When it lives in bird housing it may infest and consume dying birds, especially chicks. It was also once observed inhabiting the scrotum of a rat. The adult female beetle lays usually about 200 to 400 eggs, but it has been known to produce up to 2000. It lays eggs every few days throughout its life, which is generally up to one year long, or up to two years when it is reared in captivity. It deposits the eggs in litter, droppings, grain stores, or cracks in structures. The larvae emerge within a week and take 40 to 100 days to reach maturity, depending on conditions and the food supply. The larvae grow well in high humidity. They pupate alone in secure spots. They are quite active and mobile and burrow quickly when threatened. Larvae and adults are mainly nocturnal, becoming most active at dusk.
== Classical qualitative organic analysis == Classical qualitative organic analysis usually involves reacting an unknown sample with various reagents; a positive test usually involves a change in appearance — color, precipitation, etc. These tests may be extended to give sub-gram scale products. These products may be purified by recrystallization, and their melting points taken. An example is the formation of 2,4-dinitrophenylhydrazones from ketones and 2,4-dinitrophenylhydrazine. By consulting an appropriate reference table such as in Vogel's, the identity of the starting material may be deduced. The use of derivatives has traditionally been used to determine or confirm the identity of an unknown substance. However, due to the wide range of chemical compounds now known, it is unrealistic for these tables to be exhaustive. Modern spectroscopic and spectrometric techniques have made this technique obsolete for all but pedagogical purposes.
Secondary burial is a burial, cremation, or inhumation that is dug into a pre-existing barrow or grave any time after its initial construction. It is often associated with the belief that there is a liminal phase between the time that a person dies and finally decays.
=== Professional === Lisa attended her first IFBB professional competition at the 2014 Tampa Pro, where she placed 16th place. In 2015, Alina Popa became her coach and started training at the Armbrust PRO Gym. Her training paid off when she went on to win the 2015 Omaha Pro, the first time a professional British female bodybuilder won an overall professional competition since 1999.
Sources: en.wikipedia.org
chemical decomposition The breakdown of a single particle or entity (such as a molecule or reactive intermediate) into two or more fragments, or a chemical reaction in which two or more products are formed from a single reactant. Contrast chemical synthesis.
In order to regain thrombin responsiveness, PAR1 must be replenished in the cell surface. Uncleaved PAR1 in the cell membrane gets bound by the AP2 adaptor complex at a tyrosine motif on the intracellular C-terminus, which stimulates the endocytosis of the unactivated PAR1. It is then stored in clathrin-coated vesicles within the cytosol and ultimately protected from proteolysis. This ensures that there is a constant supply of uncleaved PAR1 that can be cycled into the plasma membrane independent of PAR1 reproduction, thus resensitizing the cell to thrombin and resetting the signal transduction pathway.
Overseas territories of European allies, including territories in Africa. "The general area of China" – Cambodia, Laos, Vietnam, Burma, and the Philippines. In the countries referred to as being in the general area of China, the Marshall Plan (ECA) operated through Special Technical and Economic Missions (STEMs). The STEMs were set up in 1950 and 1951, and had a "Point Four character" in the sense that they emphasized services by technical experts. Minimizing overlaps with the Marshall Plan, Point Four managed assistance mainly in:
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.